Li Gan

Li Gan

Auto-generated profile, based on publicly available information

Li Gan

Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, USA

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2010 in Neuron
Verified
Journal Article
Closed access
SMSang-Won Min
Sang-Won Min
SCSeo-Hyun Cho
Seo-Hyun Cho
YZYungui Zhou
Yungui Zhou
SSSebastian Schroeder
Sebastian Schroeder
VHVahram Haroutunian
Vahram Haroutunian
LGLi Gan
Li Gan

18 May 2018 in Current Protocols in Cell Biology
Verified
Journal Article
Open access
PDF file
MFMichael S. Fernandopulle
Michael S. Fernandopulle
RPRyan Prestil
Ryan Prestil
CGChristopher Grunseich
Christopher Grunseich
CWChao Wang
Chao Wang
LGLi Gan
Li Gan
MWMichael E. Ward
Michael E. Ward
Accurate modeling of human neuronal cell biology has been a long‐standing challenge. However, methods to differentiate human induced pluripotent stem cells (iPSCs) to neurons have recently provided experimentally tractable cell models. Numerous methods that use small molecules to direct iPSCs into neuronal lineages have arisen in recent years. Unfortunately, these methods entail numerous challenges, including poor efficiency, variable cell type heterogeneity, and lengthy, expensive differentiation procedures. We recently developed a new method to generate stable transgenic lines of human iPSCs with doxycycline‐inducible transcription factors at safe‐harbor loci. Using a simple two‐step protocol, these lines can be inducibly differentiated into either cortical (i3Neurons) or lower motor neurons (i3LMN) in a rapid, efficient, and scalable manner (Wang et al., 2017). In this manuscript, we describe a set of protocols to assist investigators in the culture and genetic engineering of iPSC lines to enable transcription factor–mediated differentiation of iPSCs into i3Neurons or i3LMNs, and we present neuronal culture conditions for various experimental applications. © 2018 by John Wiley & Sons, Inc.

21 September 2015 in Nature Medicine
Verified
Journal Article
Open access
PDF file
SMSang-Won Min
Sang-Won Min
XCXu Chen
Xu Chen
TTTara E Tracy
Tara E Tracy
YLYaqiao Li
Yaqiao Li
YZYungui Zhou
Yungui Zhou
LGLi Gan
Li Gan
Acetylation of tau at K174 is identified in Alzheimer's disease (AD) brain tissue and exacerbates tau-mediated neurodegeneration and memory impairments in mice. Pharmacological inhibition of tau acetylation ameliorates these phenotypes in a mouse model of AD. Tauopathies, including frontotemporal dementia (FTD) and Alzheimer's disease (AD), are neurodegenerative diseases in which tau fibrils accumulate. Recent evidence supports soluble tau species as the major toxic species. How soluble tau accumulates and causes neurodegeneration remains unclear. Here we identify tau acetylation at Lys174 (K174) as an early change in AD brains and a critical determinant in tau homeostasis and toxicity in mice. The acetyl-mimicking mutant K174Q slows tau turnover and induces cognitive deficits in vivo. Acetyltransferase p300-induced tau acetylation is inhibited by salsalate and salicylate, which enhance tau turnover and reduce tau levels. In the PS19 transgenic mouse model of FTD, administration of salsalate after disease onset inhibited p300 activity, lowered levels of total tau and tau acetylated at K174, rescued tau-induced memory deficits and prevented hippocampal atrophy. The tau-lowering and protective effects of salsalate were diminished in neurons expressing K174Q tau. Targeting tau acetylation could be a new therapeutic strategy against human tauopathies.

26 September 2018 in Nature Neuroscience
Verified
Journal Article
Closed access
PDF file
LGLi Gan
Li Gan
MCMark Cookson
Mark Cookson
LPLeonard Petrucelli
Leonard Petrucelli
ASAlbert R La Spada
Albert R La Spada

22 February 2024 in Neuron
Verified
Journal Article
Open access
CLChloe Lopez-Lee
Chloe Lopez-Lee
ETEileen Ruth S. Torres
Eileen Ruth S. Torres
GCGillian Carling
Gillian Carling
LGLi Gan
Li Gan
Alzheimer's disease (AD) and the mechanisms underlying its etiology and progression are complex and multifactorial. The higher AD risk in women may serve as a clue to better understand these complicated processes. In this review, we examine aspects of AD that demonstrate sex-dependent effects and delve into the potential biological mechanisms responsible, compiling findings from advanced technologies such as single-cell RNA sequencing, metabolomics, and multi-omics analyses. We review evidence that sex hormones and sex chromosomes interact with various disease mechanisms during aging, encompassing inflammation, metabolism, and autophagy, leading to unique characteristics in disease progression between men and women.

1 October 2017 in Stem Cell Reports
Verified
Journal Article
Open access
CWChao Wang
Chao Wang
MWMichael E. Ward
Michael E. Ward
RCRobert Chen
Robert Chen
KLKai Liu
Kai Liu
TTTara E. Tracy
Tara E. Tracy
LGLi Gan
Li Gan
Lowering total tau levels is an attractive therapeutic strategy for Alzheimer's disease and other tauopathies. High-throughput screening in neurons derived from human induced pluripotent stem cells (iPSCs) is a powerful tool to identify tau-targeted therapeutics. However, such screens have been hampered by heterogeneous neuronal production, high cost and low yield, and multi-step differentiation procedures. We engineered an isogenic iPSC line that harbors an inducible neurogenin 2 transgene, a transcription factor that rapidly converts iPSCs to neurons, integrated at the AAVS1 locus. Using a simplified two-step protocol, we differentiated these iPSCs into cortical glutamatergic neurons with minimal well-to-well variability. We developed a robust high-content screening assay to identify tau-lowering compounds in LOPAC and identified adrenergic receptors agonists as a class of compounds that reduce endogenous human tau. These techniques enable the use of human neurons for high-throughput screening of drugs to treat neurodegenerative disease.